Authors

Ivo Abraham, PhD
Ivo Abraham is chief scientist of Matrix45 and professor of pharmacy, medicine, and clinical translational sciences at the University of Arizona, where he is associated with the Center for Health Outcomes and PharmacoEconomic Research. He has worked in biologic drugs since the late 1990s and in biosimilars since their introduction in the European marketplace – collaborating closely with Karen MacDonald, who is also his wife. On both the private and academic sides, his group published the first economic evaluations of biosimilars, a line of studies that continues to date. Building on large international observational studies on biological therapies that the Abraham-MacDonald tandem implemented in the late 1990s and early 2000s, they worked with Sandoz on the MONITOR-GCSF and MONITOR-CKD-5 studies that proved to be instrumental in the breakthrough of biosimilars in Europe. As biosimilars entered the US market, Matrix45 added studies in support of biosimilar adoption in the United States. More recently, Matrix45 has ventured into biosimilars in emerging markets, including low- and middle-income countries. He may be reached at
Dan Danielson, RPh, MS
Dan Danielson, RPh, MS, has over 20 years of experience developing and leading pharmacy programs in the health plan and pharmacy benefit management (PBM) industry. At PrecisionValue, he leverages his experience in advising his clients. He is experienced in leading programs and projects in which he was accountable for forecasting the impact of high-cost pharmaceuticals, developing utilization management programs, and providing thought leadership to executive teams. He has deep experience with Pharmacy and Therapeutics (P&T) Committees, Medical Policy Committees and a Value Assessment Committee. As a recognized expert in value and technology assessment, Dan is sought out to advise and review budget impact and cost-effectiveness models.
April Breyer Menon, JD
April Breyer Menon is the founder of April Breyer Menon Consulting. At her business, she maintains a database of information related to biologic patent litigations and inter partes review proceedings and regularly writes presentations and publications related to biosimilar patent law. Breyer Menon obtained her JD degree from Boston College Law School in 2011, prior to which she attended University of Minnesote, where she graduated with a bachelor of Science in Genetics and Cell Biology and a bachelor of Arts in Physiology in 2005.
Ha Kung Wong, JD
Beyond being a member of The Center for Biosimilars® Advisory Board, Ha Kung Wong is a partner and intellectual property attourney at Venable LLP. Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation as well as intellectual property transactions and contract negotiations for mergers, acquisitions, vendor agreements and collaborations in pharmaceuticals, biologics, chemistry and medical devices. Cases Wong has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives, ADHD medications, injectable microspheres, RNAi products and other pharmaceuticals. He also has extensive experience with
Dinakaran Balasubramanian
Dinakaran is an accomplished commercial professional with rich experience of over 12 years in the pharmaceutical industry. He has an extensive understanding of the US commercial landscape and its key economic drivers, specifically in generic injectables and biosimilars. He is currently serving as the Head of Commercial Strategy & Insights for Biologics in North America for Dr Reddys Laboratories. His role extends to providing valuable insights into pricing considerations, competitive intelligence, and market dynamics, crucial for driving product adoption and profitability objectives. During his long tenure, he has handled multiple roles across Sales, strategy, pricing, and product management.